MedTrace Logo

A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL

NCT07172893 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-12-23

No results posted yet for this study

Summary

The purpose of this clinical evaluation is to collect patient outcome data and evaluate the efficacy, safety and tolerability of HealthTech DermaBind TL™ in patients with chronic non-healing wounds in patients with chronic non-healing ulcers.

Conditions

  • Diabetic Foot Ulcer (DFU)
  • Venous Leg Ulcer (VLU)

Interventions

BIOLOGICAL

DermaBind TL

Full-Thickness Dehydrated Placental Allograft

Sponsors & Collaborators

  • HealthTech Wound Care

    lead INDUSTRY

Principal Investigators

  • Stan Andrews, MS · Professional Education and Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-10
Primary Completion
2027-02-21
Completion
2027-05-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07172893 on ClinicalTrials.gov